Brief: PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency
04/03/2024 12:07
March 4 (Reuters) - PepGen Inc PEPG.O :
* PEPGEN ANNOUNCES CLEARANCE OF CTA BY UK MEDICINES &
HEALTHCARE
PRODUCTS REGULATORY AGENCY TO BEGIN CONNECT2-EDO51, A PHASE 2
CLINICAL TRIAL DESIGNED TO SUPPORT POTENTIAL ACCELERATED
APPROVAL OF PGN-EDO51 FOR THE TREATMENT OF DUCHENNE MUSCULAR
DYSTROPHY
Source text for Eikon: ID:nGNX9zBK3Z
Further company coverage: PEPG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview